JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 56(2022) N 4 p. 508-516; DOI 10.1134/S0026893322040112 Full Text

A.S. Tikhonov1*, R.R. Mintaev1,2, D.V. Glazkova1, E.V. Bogoslovskaya1, G.A. Shipulin1

HIV Restriction Factor APOBEC3G and Prospects for Its Use in Gene Therapy for HIV

1Center for Strategic Planning and Management of Medical and Biological Health Risks, Moscow, 119833 Russia
2Mechnikov Research Institute of Vaccines and Sera, Moscow, 105064 Russia

*andrey.tikhonov97@gmail.com
Received - 2021-11-27; Revised - 2022-02-11; Accepted - 2022-02-17

The mechanisms for the protection of the human body from viral or bacterial agents are extremely diverse. In one such mechanism, an important role belongs to the cytidine deaminase APOBEC3 family, which is the factor of congenital immunity and protects the organism from numerous viral agents. One of the proteins of this family, APOBEC3G, is able to protect against Human Immunodeficiency Virus type 1 in the absence of viral protein Vif. In turn, Vif opposes APOBEC3G action, causing polyubiquity of the protein and degradation in the proteasome. The review describes possible ways to increase the anti-HIV activity of APOBEC3G, giving it resistance to viral protein Vif, as well as potential approaches to the use of modified APOBEC3G in gene therapy for HIV.

APOBEC3G, APOBEC3G-D128K, gene therapy, HIV infection, Vif



JMB-FOOTER RAS-JOURNALS